Infibeta (IFN-β-1b biosimilar) / ArchiMed - LARVOL DELTA

Long-term treatment for multiple sclerosis with interferon beta-1b. Outcomes of an open, retrospective, observational study (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "The study outcomes confirm a high clinical response to the long-term treatment with Infibeta in patients with RRMS and SPMS and demonstrate that interferon beta-1b is one an optimal option for the initial treatment of patients with moderate disease activity."

Journal • Observational data • Retrospective data • CNS Disorders • Multiple Sclerosis

A study of the efficacy of infibeta in patients with multiple sclerosis based on NEDA-3 (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "During the treatment with infibeta, the chance of exacerbation decreased by an average of 39.4 times (OR 39.4 95% CI; 16.6-122.7) during the first year, by 35.3 times (OR 35.3; 95% CI 13.5-131,2) during the second year. A statistically significant decrease in the probability of exacerbation is also confirmed in the conditional logistic regression model (p<0.001). MRI revealed the signs of exacerbation and progression of the disease only in 11.5% of patients; 54.9% of the patients met the criteria NEDA-3. The highest efficacy of infibeta is noted in patients with RRS, more than / of them responded to therapy with the absence of both clinical and MRI signs of exacerbation and increase in neurodegeneration. Thus, a good clinical result is achieved in patients with RRS and SPMS treated with infibeta. When using the NEDA-3 criteria, a positive result is achieved in more than half of patients."

Clinical • Journal